EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Uncertainty and novel clinical trial designs in oncology – when should equipoise matter?

Sarah Heynemann iD, Wendy Lipworth iD, Sue-Anne McLachlan iD, Jennifer Philip iD, Tom John, Ian Kerridge

Clinical Trials · 2026

DOI: 10.1177/17407745261469887 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Trials, 2026. Verfasst von Sarah Heynemann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Health Ethics, Faculty of Medicine and Health, The University of Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Research Design, Therapeutic Equipoise, Randomized Controlled Trials as Topic, Medical Oncology. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Equipoise is usually considered a requirement for the ethical conduct of phase III randomised controlled trials. Notwithstanding theoretical critiques since the concept’s initial proposal, equipoise has remained an important moral consideration. In oncology, many research questions are now pursued via clinical trial designs that diverge in various ways from conventional, fixed-design, two-arm randomised controlled trials. In this article, we outline the challenges that these new designs pose for implementing equipoise. Specifically, we consider challenges posed by trials incorporating seamless designs, ‘immortal’ trials, and trials incorporating adaptive techniques. While we note that equipoise retains a central role in the ethical evaluation of conventional randomised controlled trials, we contend that its utility as a moral construct is challenged by more recent, ‘novel randomised controlled trial’ designs. Consequently, other ethical tools become important in considering the different types of risk that trial participants are exposed to in modern clinical trial designs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignTherapeutic EquipoiseRandomized Controlled Trials as TopicMedical OncologyClinical Trials as TopicHumansUncertaintyEthics, Research

Stichwörter der Autor:innen

adaptive trialcancerequipoiseoncologyplatform trialrandomised controlled trialresearch ethics

Autor:innen und Institutionen

  • Sydney Health Ethics, Faculty of Medicine and Health, The University of Sydney, NSW, Australia.
  • Department of Oncology, Northern Health, Melbourne, VIC, Australia.
  • Department of Philosophy, Macquarie University, Sydney, NSW, Australia.
  • Department of Medical Oncology, St Vincent's Hospital, Melbourne, VIC, Australia.
  • Department of Medicine, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, VIC, Australia.
  • Department of Palliative Care, St Vincent's Hospital, Melbourne, VIC, Australia.

ORCID-Profile: Sarah Heynemann, Wendy Lipworth, Sue-Anne McLachlan, Jennifer Philip

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Heynemann, S., Lipworth, W., McLachlan, S. A., Philip, J., John, T., & Kerridge, I. (2026). Uncertainty and novel clinical trial designs in oncology – when should equipoise matter?. Clinical Trials. https://doi.org/10.1177/17407745261469887

Vancouver

Heynemann S, Lipworth W, McLachlan SA, Philip J, John T, Kerridge I. Uncertainty and novel clinical trial designs in oncology – when should equipoise matter?. Clinical Trials. 2026. doi:10.1177/17407745261469887

BibTeX
@article{Heynemann2026,
  author = {Heynemann, Sarah and Lipworth, Wendy and McLachlan, Sue-Anne and Philip, Jennifer and John, Tom and Kerridge, Ian},
  title = {Uncertainty and novel clinical trial designs in oncology – when should equipoise matter?},
  journal = {Clinical Trials},
  year = {2026},
  doi = {10.1177/17407745261469887}
}
Kostenlos starten →